FDA grants fast-track status for Nektar drug

Filed under: drug treatment programs

Nektar Therapeutics (NASDAQ:NKTR) has received fast-track development program designation from the U.S. Food and Drug Administration on a drug designed to treat patients with a type of breast… Continue reading →